Your browser doesn't support javascript.
loading
Neurological Involvement in Malignant Atrophic Papulosis: A Comprehensive Review of Literature.
Yousefi, Samaneh; Borhani-Haghighi, Afshin; Safari, Anahid; Shapiro, Lee.
Afiliación
  • Yousefi S; Student Research Committee, Fasa University of Medical Sciences, Fasa, Iran.
  • Borhani-Haghighi A; Clinical Neurology Research Center; Deparment of Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Safari A; Stem Cells Technology Reseach Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Shapiro L; Albany Medical College, Albany, New York, USA.
Neurol India ; 70(1): 5-10, 2022.
Article en En | MEDLINE | ID: mdl-35263846
ABSTRACT
Malignant atrophic papulosis (MAP), or systemic Degos disease, is an obliterative vasculopathy of unknown origin, characterized by erythematous papules found on the skin, central nervous system (Neuro-MAP) and gastrointestinal tract. Neurological involvement occurs in approximately 20% of systemic cases, is progressive and largely fatal. It can be described in two forms 1) the parenchymal presenting with meningoencephalitis and meningomyelitis and 2) the neurovascular presenting with large cerebral infarcts, intracranial and subarachnoid hemorrhage, subdural hematoma and venous sinus thrombosis. Predilection to subdural hematoma or hygroma is characteristic for neurological involvement in MAP in comparison to other vasculpathies and vasculitides. Peripheral nervous system manifestations are less common and include polyradiculopathy, neuropathy, and myopathy. CSF analysis usually shows mild to moderate pleocytosis, increased protein content, and normal glucose. Brain MRI may reveal cortical, subcortical and deep white matter ischemic lesions with possible nodular, leptomeningeal, dural, or ependymal enhancement. Spinal cord MRI may reveal patchy lesions from the periphery to the center or cord atrophy in progressive course. Neurological involvement in MAP has a grave prognosis. The interval from onset of papulosis to death averages two years in patients with neurological involvement. There is no confirmed treatment for MAP but there are promising reports with eculizumab and treprostinil.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Papulosis Atrófica Maligna Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Neurol India Año: 2022 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Papulosis Atrófica Maligna Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Neurol India Año: 2022 Tipo del documento: Article País de afiliación: Irán